Allogene Therapeutics Inc

ALLO

Add to Watchlist

2.000USD

-0.140-6.54%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Allogene Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

133 / 382

Overall Ranking

262 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Allogene Therapeutics Inc Highlights

StrengthsRisks

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Undervalued

The company’s latest PE is -2.61, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 152.15M shares, decreasing 18.15% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 8.85K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.90.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

8.488

Target Price

+296.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Allogene Therapeutics Inc is 5.10, ranking 369 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.10

Change

0



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.36

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Allogene Therapeutics Inc is 8.08, ranking 62 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.61, which is -70.01% below the recent high of -0.78 and -32.08% above the recent low of -3.45.

Score

Industry at a Glance

Previous score

8.08

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 133/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Allogene Therapeutics Inc is 8.27, ranking 142 out of 382 in the Biotechnology & Medical Research industry. The average price target is 7.50, with a high of 14.00 and a low of 1.60.

Score

Industry at a Glance

Previous score

8.27

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Allogene Therapeutics Inc is 6.39, ranking 247 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.38 and the support level at 1.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.42

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Allogene Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 44.66%, representing a quarter-over-quarter decrease of 45.84%. The largest institutional shareholder is PRIMECAP Management, holding a total of 8.38M shares, representing 2.43% of shares outstanding, with 7.72% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Pfizer Inc

22.03M

--

TPG Capital, L.P.

18.72M

--

Frazier Life Sciences Management, L.P.

3.87M

--

Citadel Advisors LLC

12.11M

-13.31%

BlackRock Institutional Trust Company, N.A.

11.46M

+2.81%

PRIMECAP Management Company

Star Investors

8.14M

+14.98%

Belldegrun (Arie S)

7.56M

--

Two Sigma Investments, LP

6.33M

+2.22%

Chang (David D)

5.58M

-0.85%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Allogene Therapeutics Inc is 3.70, ranking 118 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Allogene Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Allogene Therapeutics Inc

ALLO

6.09 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment